Primary cutaneous marginal zone lymphoma

Critical Reviews in Oncology/Hematology

Volumn 74, Issue 3, 2010, Pages 156-162

  Dalle, Stéphane ^a   Thomas, Luc ^a   Balme, Brigitte ^a   Dumontet, Charles ^a   Thieblemont, Catherine ^b  

^a UNIVERSITÉ LYON 1   (France)

^b SAINT LOUIS HOSPITAL   (France)

Author keywords

Cutaneous lymphoma; Marginal zone lymphoma; Review; Rituximab

Indexed keywords

ANTIBIOTIC AGENT; CD20 ANTIGEN; CD22 ANTIGEN; CD23 ANTIGEN; CD5 ANTIGEN; CD79A ANTIGEN; COMMON ACUTE LYMPHOBLASTIC LEUKEMIA ANTIGEN; COMPLEMENT COMPONENT C3D RECEPTOR; CYCLINE; CYCLOPHOSPHAMIDE; CYCLOSPORIN; DOXORUBICIN; IMMUNOGLOBULIN HEAVY CHAIN; PREDNISONE; PROTEIN BCL 2; PROTEIN BCL 6; RITUXIMAB; VINCRISTINE SULFATE;

ANTIGEN EXPRESSION; BORRELIA BURGDORFERI; CANCER RADIOTHERAPY; CANCER STAGING; CANCER SURVIVAL; DISEASE FREE SURVIVAL; GENE LOCUS; HISTOPATHOLOGY; HUMAN; IMMUNOPHENOTYPING; IMMUNOSTIMULATION; MARGINAL ZONE LYMPHOMA; MUCOSA ASSOCIATED LYMPHOID TISSUE LYMPHOMA; NODAL MARGINAL ZONE LYMPHOMA; PAPULE; PATHOGENESIS; PERIODIC ACID SCHIFF STAIN; PRIMARY CUTANEOUS MARGINAL ZONE LYMPHOMA; PROGNOSIS; RADIATION DOSE FRACTIONATION; REVIEW; TUMOR LOCALIZATION;

HUMANS; IMMUNOPHENOTYPING; LYMPHOMA; PROGNOSIS; SKIN NEOPLASMS;

EID: 77953356687     PISSN: 10408428     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.critrevonc.2009.09.003     Document Type: Review

References (77)

1. Isaacson P., Wright D.H. Malignant lymphoma of mucosa-associated lymphoid tissue. A distinctive type of B-cell lymphoma. Cancer 1983, 52:1410-1416.
2. A clinical evaluation of the International Lymphoma Study Group classification of non-Hodgkin's lymphoma. The Non-Hodgkin's Lymphoma Classification Project. Blood 1997;89:3909-18.
3. Pelstring R.J., Essell J.H., Kurtin P.J., et al. Diversity of organ site involvement among malignant lymphomas of mucosa-associated tissues. Am J Clin Pathol 1991, 96:738-745.
4. Bailey E.M., Ferry J.A., Harris N.L., et al. Marginal zone lymphoma (low-grade B-cell lymphoma of mucosa-associated lymphoid tissue type) of skin and subcutaneous tissue: a study of 15 patients. Am J Surg Pathol 1996, 20:1011-1023.
5. Willemze R., Jaffe E.S., Burg G., et al. WHO-EORTC classification for cutaneous lymphomas. Blood 2005, 105:3768-3785.
6. Rijlaarsdam J.U., van der Putte S.C., Berti E., et al. Cutaneous immunocytomas: a clinicopathologic study of 26 cases. Histopathology 1993, 23:117-125.
7. Fink-Puches R., Zenahlik P., Back B., et al. Primary cutaneous lymphomas: applicability of current classification schemes (European Organization for Research and Treatment of Cancer. World Health Organization) based on clinicopathologic features observed in a large group of patients. Blood 2002, 99:800-805.
8. Martin F., Kearney J.F. Marginal-zone B cells. Nat Rev Immunol 2002, 2:323-335.
9. Pillai S., Cariappa A., Moran S.T. Marginal zone B cells. Annu Rev Immunol 2005, 23:161-196.
10. Martin F., Oliver A.M., Kearney J.F. Marginal zone and B1 B cells unite in the early response against T-independent blood-borne particulate antigens. Immunity 2001, 14:617-629.
11. Weller S., Reynaud C.A., Weill J.C. Splenic marginal zone B cells in humans: where do they mutate their Ig receptor?. Eur J Immunol 2005, 35:2789-2792.
12. Ferreri A.J., Ernberg I., Copie-Bergman C. Infectious agents and lymphoma development: molecular and clinical aspects. J Intern Med 2009, 265:421-438.
13. Jelic S., Filipovic-Ljeskovic I. Positive serology for Lyme disease borrelias in primary cutaneous B-cell lymphoma: a study in 22 patients, is it a fortuitous finding?. Hematol Oncol 1999, 17:107-116.
14. Goodlad J.R., Davidson M.M., Hollowood K., et al. Borrelia burgdorferi-associated cutaneous marginal zone lymphoma: a clinicopathological study of two cases illustrating the temporal progression of B. burgdorferi-associated B-cell proliferation in the skin. Histopathology 2000, 37:501-508.
15. Goodlad J.R., Davidson M.M., Hollowood K., et al. Primary cutaneous B-cell lymphoma and Borrelia burgdorferi infection in patients from the Highlands of Scotland. Am J Surg Pathol 2000, 24:1279-1285.
16. Cerroni L., Zochling N., Putz B., et al. Infection by Borrelia burgdorferi and cutaneous B-cell lymphoma. J Cutan Pathol 1997, 24:457-461.
17. Garbe C., Stein H., Dienemann D., et al. Borrelia burgdorferi-associated cutaneous B cell lymphoma: clinical and immunohistologic characterization of four cases. J Am Acad Dermatol 1991, 24:584-590.
18. de la Fouchardiere A., Vandenesch F., Berger F. Borrelia-associated primary cutaneous MALT lymphoma in a nonendemic region. Am J Surg Pathol 2003, 27:702-703.
19. Roggero E., Zucca E., Mainetti C., et al. Eradication of Borrelia burgdorferi infection in primary marginal zone B-cell lymphoma of the skin. Hum Pathol 2000, 31:263-268.
20. Stanek G., Strle F. Lyme borreliosis. Lancet 2003, 362:1639-1647.
21. Colli C., Leinweber B., Mullegger R., et al. Borrelia burgdorferi-associated lymphocytoma cutis: clinicopathologic, immunophenotypic, and molecular study of 106 cases. J Cutan Pathol 2004, 31:232-240.
22. Li C., Inagaki H., Kuo T.T., et al. Primary cutaneous marginal zone B-cell lymphoma: a molecular and clinicopathologic study of 24 Asian cases. Am J Surg Pathol 2003, 27:1061-1069.
23. Wood G.S., Kamath N.V., Guitart J., et al. Absence of Borrelia burgdorferi DNA in cutaneous B-cell lymphomas from the United States. J Cutan Pathol 2001, 28:502-507.
24. Monari P., Farisoglio C., Calzavara Pinton P.G. Borrelia burgdorferi-associated primary cutaneous marginal-zone B-cell lymphoma: a case report. Dermatology 2007, 215:229-232.
25. Bahler D.W., Kim B.K., Gao A., et al. Analysis of immunoglobulin V genes suggests cutaneous marginal zone B-cell lymphomas recognise similar antigens. Br J Haematol 2006, 132:571-575.
26. Kutting B., Bonsmann G., Metze D., et al. Borrelia burgdorferi-associated primary cutaneous B cell lymphoma: complete clearing of skin lesions after antibiotic pulse therapy or intralesional injection of interferon alfa-2a. J Am Acad Dermatol 1997, 36:311-314.
27. Nihal M., Mikkola D., Horvath N., et al. Cutaneous lymphoid hyperplasia: a lymphoproliferative continuum with lymphomatous potential. Hum Pathol 2003, 34:617-622.
28. Grange F., Wechsler J., Guillaume J.C., et al. Borrelia burgdorferi-associated lymphocytoma cutis simulating a primary cutaneous large B-cell lymphoma. J Am Acad Dermatol 2002, 47:530-534.
29. Suarez F., Lortholary O., Hermine O., et al. Infection-associated lymphomas derived from marginal zone B cells: a model of antigen-driven lymphoproliferation. Blood 2006, 107:3034-3044.
30. Fink-Puches R., Chott A., Ardigo M., et al. The spectrum of cutaneous lymphomas in patients less than 20 years of age. Pediatr Dermatol 2004, 21:525-533.
31. Dargent J.L., Devalck C., De Mey A., et al. Primary cutaneous marginal zone B-cell lymphoma of MALT type in a child. Pediatr Dev Pathol 2006, 9:468-473.
32. Zinzani P.L., Quaglino P., Pimpinelli N., et al. Prognostic factors in primary cutaneous B-cell lymphoma: the Italian Study Group for Cutaneous Lymphomas. J Clin Oncol 2006, 24:1376-1382.
33. Bathelier E., Thomas L., Balme B., et al. Marginal zone B-cell lymphoma affecting the skin: histological and phenotypic study of 49 cases. Ann Dermatol Venereol 2008, 135:748-752.
34. Servitje O., Gallardo F., Estrach T., et al. Primary cutaneous marginal zone B-cell lymphoma: a clinical, histopathological, immunophenotypic and molecular genetic study of 22 cases. Br J Dermatol 2002, 147:1147-1158.
35. Cho-Vega J.H., Vega F., Rassidakis G., et al. Primary cutaneous marginal zone B-cell lymphoma. Am J Clin Pathol 2006, 125(Suppl.):S38-S49.
36. Hoefnagel J.J., Vermeer M.H., Jansen P.M., et al. Bcl-2, Bcl-6 and CD10 expression in cutaneous B-cell lymphoma: further support for a follicle centre cell origin and differential diagnostic significance. Br J Dermatol 2003, 149:1183-1191.
37. de Leval L., Harris N.L., Longtine J., et al. Cutaneous b-cell lymphomas of follicular and marginal zone types: use of Bcl-6, CD10, Bcl-2, and CD21 in differential diagnosis and classification. Am J Surg Pathol 2001, 25:732-741.
38. Gallardo F., Bellosillo B., Espinet B., et al. Aberrant nuclear BCL10 expression and lack of t(11, 18)(q21, q21) in primary cutaneous marginal zone B-cell lymphoma. Hum Pathol 2006, 37:867-873.
39. van Maldegem F., van Dijk R., Wormhoudt T.A., et al. The majority of cutaneous marginal zone B-cell lymphomas expresses class-switched immunoglobulins and develops in a T-helper type 2 inflammatory environment. Blood 2008, 112:3355-3361.
40. Streubel B., Lamprecht A., Dierlamm J., et al. T(14, 18)(q32, q21) involving IGH and MALT1 is a frequent chromosomal aberration in MALT lymphoma. Blood 2003, 101:2335-2339.
41. Streubel B., Vinatzer U., Lamprecht A., et al. T(3, 14)(p14.1, q32) involving IGH and FOXP1 is a novel recurrent chromosomal aberration in MALT lymphoma. Leukemia 2005, 19:652-658.
42. Deutsch A.J., Fruhwirth M., Aigelsreiter A., et al. Primary cutaneous marginal zone B-cell lymphomas are targeted by aberrant somatic hypermutation. J Invest Dermatol 2008.
43. Liu M., Duke J.L., Richter D.J., et al. Two levels of protection for the B cell genome during somatic hypermutation. Nature 2008, 451:841-845.
44. Pasqualucci L., Bhagat G., Jankovic M., et al. AID is required for germinal center-derived lymphomagenesis. Nat Genet 2008, 40:108-112.
45. Pasqualucci L., Neumeister P., Goossens T., et al. Hypermutation of multiple proto-oncogenes in B-cell diffuse large-cell lymphomas. Nature 2001, 412:341-346.
46. Gaidano G., Pasqualucci L., Capello D., et al. Aberrant somatic hypermutation in multiple subtypes of AIDS-associated non-Hodgkin lymphoma. Blood 2003, 102:1833-1841.
47. Dijkman R., Tensen C.P., Buettner M., et al. Primary cutaneous follicle center lymphoma and primary cutaneous large B-cell lymphoma, leg type, are both targeted by aberrant somatic hypermutation but demonstrate differential expression of AID. Blood 2006, 107:4926-4929.
48. Bodor C., Bognar A., Reiniger L., et al. Aberrant somatic hypermutation and expression of activation-induced cytidine deaminase mRNA in mediastinal large B-cell lymphoma. Br J Haematol 2005, 129:373-376.
49. Deutsch A.J., Aigelsreiter A., Staber P.B., et al. MALT lymphoma and extranodal diffuse large B-cell lymphoma are targeted by aberrant somatic hypermutation. Blood 2007, 109:3500-3504.
50. Halldorsdottir A.M., Fruhwirth M., Deutsch A., et al. Quantifying the role of aberrant somatic hypermutation in transformation of follicular lymphoma. Leuk Res 2008, 32:1015-1021.
51. Gronbaek K., Ralfkiaer E., Kalla J., et al. Infrequent somatic Fas mutations but no evidence of Bcl10 mutations or t(11, 18) in primary cutaneous MALT-type lymphoma. J Pathol 2003, 201:134-140.
52. Hallermann C., Kaune K.M., Gesk S., et al. Molecular cytogenetic analysis of chromosomal breakpoints in the IGH, MYC, BCL6, and MALT1 gene loci in primary cutaneous B-cell lymphomas. J Invest Dermatol 2004, 123:213-219.
53. Espinet B., Gallardo F., Pujol R.M., et al. Absence of MALT1 translocations in primary cutaneous marginal zone B-cell lymphoma. Haematologica 2004, 89:ELT14.
54. Arcaini L., Burcheri S., Rossi A., et al. Nongastric marginal-zone B-cell MALT lymphoma: prognostic value of disease dissemination. Oncologist 2006, 11:285-291.
55. Thieblemont C., Berger F., Dumontet C., et al. Mucosa-associated lymphoid tissue lymphoma is a disseminated disease in one third of 158 patients analyzed. Blood 2000, 95:802-806.
56. Zucca E., Conconi A., Pedrinis E., et al. Nongastric marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue. Blood 2003, 101:2489-2495.
57. Kim Y.H., Willemze R., Pimpinelli N., et al. TNM classification system for primary cutaneous lymphomas other than mycosis fungoides and Sezary syndrome: a proposal of the International Society for Cutaneous Lymphomas (ISCL) and the Cutaneous Lymphoma Task Force of the European Organization of Research and Treatment of Cancer (EORTC). Blood 2007, 110:479-484.
58. Bathelier E., Thomas L., Balme B., et al. Asymptomatic bone marrow involvement in patients presenting with cutaneous marginal zone B-cell lymphoma. Br J Dermatol 2008, 159:498-500.
59. Senff N.J., Kluin-Nelemans H.C., Willemze R. Results of bone marrow examination in 275 patients with histological features that suggest an indolent type of cutaneous B-cell lymphoma. Br J Haematol 2008, 142:52-56.
60. Bertoni F., Zucca E. State-of-the-art therapeutics: marginal-zone lymphoma. J Clin Oncol 2005, 23:6415-6420.
61. Grunberger B., Wohrer S., Streubel B., et al. Antibiotic treatment is not effective in patients infected with Helicobacter pylori suffering from extragastric MALT lymphoma. J Clin Oncol 2006, 24:1370-1375.
62. Dreno B. Standard and new treatments in cutaneous B-cell lymphomas. J Cutan Pathol 2006, 33(Suppl. 1):47-51.
63. Zenahlik P., Fink-Puches R., Kapp K.S., et al. Therapy of primary cutaneous B-cell lymphomas. Hautarzt 2000, 51:19-24.
64. Hoefnagel J.J., Vermeer M.H., Jansen P.M., et al. Primary cutaneous marginal zone B-cell lymphoma: clinical and therapeutic features in 50 cases. Arch Dermatol 2005, 141:1139-1145.
65. Senff N.J., Noordijk E.M., Kim Y.H., et al. European Organization for Research and Treatment of Cancer and International Society for Cutaneous Lymphoma consensus recommendations for the management of cutaneous B-cell lymphomas. Blood 2008, 112:1600-1609.
66. Thieblemont C., Coiffier B. Management of marginal zone lymphomas. Curr Treat Options Oncol 2006, 7:213-222.
67. Senff N.J., Hoefnagel J.J., Neelis K.J., et al. Results of radiotherapy in 153 primary cutaneous B-Cell lymphomas classified according to the WHO-EORTC classification. Arch Dermatol 2007, 143:1520-1526.
68. Cozzio A., Kempf W., Schmid-Meyer R., et al. Intra-lesional low-dose interferon alpha2a therapy for primary cutaneous marginal zone B-cell lymphoma. Leuk Lymphoma 2006, 47:865-869.
69. Conconi A., Martinelli G., Thieblemont C., et al. Clinical activity of rituximab in extranodal marginal zone B-cell lymphoma of MALT type. Blood 2003, 102:2741-2745.
70. Valencak J., Weihsengruber F., Rappersberger K., et al. Rituximab monotherapy for primary cutaneous B-cell lymphoma: response and follow-up in 16 patients. Ann Oncol 2008.
71. Gellrich S., Muche J.M., Wilks A., et al. Systemic eight-cycle anti-CD20 monoclonal antibody (rituximab) therapy in primary cutaneous B-cell lymphomas-an applicational observation. Br J Dermatol 2005, 153:167-173.
72. Soda R., Costanzo A., Cantonetti M., et al. Systemic therapy of primary cutaneous B-cell lymphoma, marginal zone type, with rituximab, a chimeric anti-CD20 monoclonal antibody. Acta Derm Venereol 2001, 81:207-208.
73. Kyrtsonis M.C., Siakantaris M.P., Kalpadakis C., et al. Favorable outcome of primary cutaneous marginal zone lymphoma treated with intralesional rituximab. Eur J Haematol 2006, 77:300-303.
74. Kerl K., Prins C., Saurat J.H., et al. Intralesional and intravenous treatment of cutaneous B-cell lymphomas with the monoclonal anti-CD20 antibody rituximab: report and follow-up of eight cases. Br J Dermatol 2006, 155:1197-1200.
75. Gronbaek K., Moller P.H., Nedergaard T., et al. Primary cutaneous B-cell lymphoma: a clinical, histological, phenotypic and genotypic study of 21 cases. Br J Dermatol 2000, 142:913-923.
76. Sah A., Barrans S.L., Parapia L.A., et al. Cutaneous B-cell lymphoma: pathological spectrum and clinical outcome in 51 consecutive patients. Am J Hematol 2004, 75:195-199.
77. Stanway A., Rademaker M., Kennedy I., et al. Cutaneous B-cell lymphoma of nails, pinna and nose treated with chlorambucil. Aust J Dermatol 2004, 45:110-113.